PD-L1 is uniquely expressed at high levels in cancers; therefore, therapies targeting PD-1/PD-L1 have been shown to promote remarkable antitumour immunity and acquire promising therapeutic outcomes for several malignant tumours [14, 42]. The gene discussed is CD274; the disease is cancer.